In addition, specific immune checkpoint inhibitors such as CTLA-4, PD-1, and PD-L1 have dramatically changed the current status of cancer treatment and are beneficial for the overall survival (OS) of a variety of patients with cancer [8, 9]. This evidence concerns the gene CTLA4 and cancer.